NCT03819452 (IVASTO) is a clinical trial of Vitamin D Level in Ischemic Stroke, sponsored by Abha International Private Hospital.

Who is sponsoring NCT03819452?

NCT03819452 is sponsored by Abha International Private Hospital.

What drugs are being tested in NCT03819452?

Interventions in NCT03819452: Vitamin D Level.

What condition does NCT03819452 study?

NCT03819452 studies Ischemic Stroke.

Is NCT03819452 still recruiting?

NCT03819452 is currently completed. Last updated 28 January 2019.

Last reviewed 2019-01-28 · How we verify

NCT03819452: IVASTO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Vitamin D on Acute Ischemic Stroke Prognosis

Completed Last updated 28 January 2019

What this trial tests

trial testing Vitamin D Level in Ischemic Stroke in 59 participants. Completed in 25 January 2019.

Timeline

1 August 2018

Primary endpoint
25 January 2019

25 January 2019

Quick facts

Lead sponsor	Abha International Private Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	59
Start date	1 August 2018
Primary completion	25 January 2019
Estimated completion	25 January 2019
Sites	2 locations across Switzerland, Egypt

Drugs / interventions tested

Vitamin D Level

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Abha International Private Hospital

Who can join

Eligibility, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a registry for all patients admitted to hospital settings with Ischemic stroke in Mansoura University Hospital. The registry will capture patients' data, investigations and vitamin D level on admission. Follow-up is taking place using MODIFIED RANKIN SCALE

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Abha International Private Hospital trials

Trials by the same sponsor.

NCT04454541 — Efficacy of Ultrasound-Guided Multifidus Cervicis Plan Block Vs Greater Occipital Nerve Block for Cervicogenic Headache · NA · completed
NCT03580252 — Reliability of Hammersmith Examination in Prediction of Neurological Outcomes (REHAPENO) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03819452 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abha International Private Hospital
Last refreshed: 28 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03819452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing